We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

OSE Immunotherapeutics (OSE) EUR0.2

Sell:€6.83 Buy:€6.85 Change: €0.25 (3.79%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.25 (3.79%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.25 (3.79%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

Contact details

22, boulevard Benoni Goullin
+33 (2) 28291010

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€122.28 million
Shares in issue:
18.50 million
Euronext Paris

Key personnel

  • Dominique Costantini
    Chairman of the Board, Chief Executive Officer, Directorof Development, Member of the Management Board
  • Maryvonne Hiance
    Vice Chairman of the Board, Director - Public Relations, Member of the Management Board
  • Anne-Laure Autret-Cornet
    Chief Financial Officer, Member of the Management Board
  • Nicolas Poirier
    Chief Scientific Officer, Director - Representing the employee shareholders
  • Laurence De Schoulepnikoff
    Chief Business Officer
  • Jean-Pascal Conduzorgues
    Industrial Director, Qualified Pharmacist, Member of the Management Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.